5-氨基苯并[d]噁唑-2-羧酸甲酯 | 1035093-77-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: 5-氨基苯并[d]噁唑-2-羧酸甲酯
• 英文名称: methyl 5-amino-1,3-benzoxazole-2-carboxylate
• 英文别名: Methyl 5-aminobenzo[d]oxazole-2-carboxylate
• CAS: 1035093-77-6
• 化学式: C₉H₈N₂O₃
• mdl: MFCD11506182
• 分子量: 192.174
• InChiKey: BEAHBHCSAFZHKO-UHFFFAOYSA-N

物化性质

• 沸点：
  356.0±34.0 °C(Predicted)
• 密度：
  1.375±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-氨基苯并[d]噁唑-2-羧酸甲酯 在 methyl magnesium (1+); bromide 作用下， 生成 2-(5-amino-1,3-benzoxazol-2-yl)propan-2-ol
  参考文献：
  名称：

  THERAPEUTIC AGENT FOR TAUOPATHIES

  摘要：

  本发明提供了一种通过激活电压门控钠通道（Nav）治疗和/或预防tau病的药物。本发明涉及一种治疗和/或预防tau病的药物，其包括Nav激活剂作为活性成分。

  公开号：

  EP4104861A1

文献信息

• [EN] POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS<br/>[FR] AMIDES POLYCYCLIQUES SERVANT D'AGENTS CYTOTOXIQUES
  申请人：FEMTOGENIX LTD

  公开号：WO2020049286A1

  公开（公告）日：2020-03-12

  The invention relates to a compound of formula (I): or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers or mixtures thereof; wherein the fused ring moiety is a non-alkylating moiety; and wherein the compounds are useful as medicaments, in particular for use as a drug in an antibody-drug conjugate and in the treatment of a proliferative disease, a bacterial infection, a malarial infection and inflammation.

  该发明涉及公式(I)的化合物；或其药学上可接受的盐、溶剂合物、互变异构体、立体异构体或它们的混合物；其中融合环基团是非烷基化基团；这些化合物可用作药物，特别是用作抗体药物结合物中的药物，以及用于治疗增殖性疾病、细菌感染、疟疾感染和炎症。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE
  申请人：METHYLGENE INC

  公开号：WO2005092899A1

  公开（公告）日：2005-10-06

  The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

  这项发明涉及一系列对抑制组蛋白去乙酰化酶（HDAC）酶活性有用的化合物。该发明还提供了一种利用这些化合物抑制细胞中组蛋白去乙酰化酶的方法，以及一种利用这些HDAC抑制剂治疗细胞增殖性疾病和病况的方法。此外，该发明提供了包含这些HDAC抑制化合物和药用可接受载体的药物组合物。
• Inhibitors of histone deacetylase
  申请人：Delorme Daniel

  公开号：US20050245518A1

  公开（公告）日：2005-11-03

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  该发明涉及抑制组蛋白去乙酰化酶。该发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。该发明还提供了用于治疗细胞增殖性疾病和状况的组合物和方法。
• CBI analogs of CC-1065 and the duocarmycins
  申请人：The Scripps Research Institute

  公开号：US20040002528A1

  公开（公告）日：2004-01-01

  Analogs of the antitumor antibiotics CC-1065 and the duocarmycins incorporate the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) alkylation subunit. The CBI-based analogs have potent cytotoxic activity and are useful as efficacious antitumor compounds. A direct relationship between functional stability and in vitro cytotoxic potency is disclosed. The CBI-based analogs are easily synthesized and are 4× more stable and 4× more potent than the corresponding analogs containing the authentic CPI alkylation subunit of CC-1065 and comparable in potency to agents containing the authentic alkylation subunit of duocarmycin SA. Similarly, the CBI-based agents alkylate DNA with an unaltered sequence selectivity at an enhanced rate and with a greater efficiency than the corresponding CPI analog and were comparable to the corresponding analog incorporating the duocarmycin SA alkylation subunit. Systematic and extensive modifications and simplifications in the DNA binding subunits attached to CBI are also described.

  抗肿瘤抗生素CC-1065和Duocarmycins的类似物包含1,2,9,9a-四氢环丙[c]苯[e]吲哚-4-酮（CBI）烷基化亚单位。基于CBI的类似物具有强效的细胞毒性活性，可用作有效的抗肿瘤化合物。揭示了功能稳定性和体外细胞毒性效力之间的直接关系。基于CBI的类似物易于合成，比含有CC-1065的真实CPI烷基化亚单位的相应类似物稳定性和效力高4倍，并与含有Duocarmycin SA真实烷基化亚单位的药物效力相当。同样，基于CBI的药物以不改变序列选择性的增强速率和更高效率烷基化DNA，并与相应的CPI类似物相当，并与包含Duocarmycin SA烷基化亚单位的相应类似物相当。还描述了附加到CBI的DNA结合亚单位的系统性和广泛性修改和简化。
• Inhibitors of Histone Deacetylase
  申请人：Delorme Daniel

  公开号：US20070213330A1

  公开（公告）日：2007-09-13

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶的技术。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。